The prognostic role of metastatic lymph node immunological status in clinical stage III melanoma patients.

Problem The nasopharyngeal carcinoma (NPC) has been a rare cancer in the world. The incidence is higher in the southern Asiatic, Groveland and Tunisia. The age range follows the bimodal distribution. It appears most frequently in males, with a ratio of 3:1. Carcinogenic factors such as tobacco and alcohol have a role of little importance in the carcinogenesis of nasopharyngeal undifferentiated carcinoma. The diagnosis has gotten in elderly phase, named noiseless phase of growing and is not common the initial presentation with metastatic lymph node in the neck. The aim of this study was the assessment of demographic, clinical and treatment factors of nasopharyngeal undifferentiated carcinoma in Department of Head and Neck Surgical and Otorrinolaryngology of Heliópolis Heliópolis-Hosphel. Methods This was the retrospective study of 46 patients on January 1998 to august 2000. All patients with nasopharyngeal carcinoma had presented histopathological diagnostic of undifferentiated type. The treatment was the radiotherapy concomitant to chemotherapy to the clinical stage III and IV. Statistic analysis: Kaplan-Meier methods. Results The symptom of the most importance was the lymph node of neck. The local recurrences were not retreat and three of four regional recurrences were treated with neck dissection. All patients that spread out distance metastasis had presented loco-regional control. Conclusion The tobacco and alcohol were not factors related to disease presentation. The survival free of disease to three years was of 52%. Significance The incidence, clinical factors and treatments and survival among patients with nasopharyngeal undifferentiated carcinoma.

Download Full-text

Correlation of prevalence of CD68+ macrophages within tumor-draining lymph node basins and overall survival in stage III melanoma patients.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.e21034 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. e21034-e21034 ◽

Cited By ~ 1

Author(s):

G. Lizee ◽

M. A. Whittington ◽

J. Chen ◽

V. R. Greene ◽

S. Liu ◽

...

Keyword(s):

Overall Survival ◽

Lymph Node ◽

Stage Iii ◽

Draining Lymph Node ◽

Melanoma Patients ◽

Tumor Draining Lymph Node ◽

Stage Iii Melanoma

Download Full-text

Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.9503 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. 9503-9503 ◽

Cited By ~ 18

Author(s):

Alexander M. Menzies ◽

Elisa A. Rozeman ◽

Rodabe Navroze Amaria ◽

Alexander Chan Chi Huang ◽

Richard A. Scolyer ◽

...

Keyword(s):

Targeted Therapy ◽

Clinical Stage ◽

Complete Response ◽

Pooled Analysis ◽

Stage Iii ◽

Post Surgery ◽

Neoadjuvant Immunotherapy ◽

Neoadjuvant Systemic Therapy ◽

Melanoma Patients ◽

Stage Iii Melanoma

9503 Background: Pathological complete response (pCR) to neoadjuvant systemic therapy (NST) correlates with survival, and is recognized as a path to regulatory approval in several cancers. Recent trials have reported that neoadjuvant immunotherapy (IT) and targeted therapy (TT) regimens achieve high pCR rates and impressive recurrence-free survival in stage III melanoma, however, the relationship between pCR, relapse-free (RFS) and overall survival (OS) in larger datasets of melanoma patients (pts) remains unknown. Methods: We pooled data from 6 modern NST clinical trials of anti-PD-1 based immunotherapy or BRAF/MEK targeted therapy conducted across institutions participating in the INMC. Pts with RECIST measurable, surgically resectable clinical stage III melanoma who underwent surgery were included. NST regimens included nivolumab (as monotherapy or in combination with ipilimumab), pembrolizumab or dabrafenib+trametinib. Baseline disease characteristics, treatment regimen, pCR and RFS were examined. Results: 184 pts with clinical stage III melanoma (AJCCv7: 100 IIIB, 84 IIIC) completed NST (133 IT, 51 TT) and underwent surgery. Median age was 57y (range 18-87). A pCR was observed in 41% of patients; 51 (38%) with IT and 24 (47%) with TT. Median follow-up post-surgery is 13 mo (95% CI 12-16); 10 mo with IT and 22 mo with TT. 44 (24%) pts have recurred (17 loco-regional, 21 distant, 6 both sites at first recurrence), 18 (14%) after IT and 26 (51%) after TT. 12-month RFS was improved with IT vs TT (83% vs 65%, p < 0.001). For those with pCR, 7% have recurred, 0/51 (0%) after IT, 7/17 (41%) after TT. For those without pCR, 34% have recurred, 18/82 (22%) after IT and 19/27 (70%) after TT. 12-month RFS was improved in those with pCR vs without pCR (95% vs 62%, p < 0.001), including in those with IT (100% vs 72%, p < 0.001) and TT (88% vs 43%, p < 0.001). 16 (9%) patients have died including two who had a pCR, both from TT. Conclusions: Neoadjuvant IT and TT are active regimens in resectable clinical stage III melanoma patients and are associated with high pCR rate. The ability to achieve pCR correlates with improved RFS and remarkably no patient with pCR from immunotherapy has recurred to date.

Download Full-text